BioSpecifics Technologies (BioSpecifics Technologies) Retained Earnings : $106.65 Mil (As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BioSpecifics Technologies's retained earnings for the quarter that ended in Sep. 2020 was $106.65 Mil.

BioSpecifics Technologies's quarterly retained earnings increased from Mar. 2020 ($101.15 Mil) to Jun. 2020 ($101.26 Mil) and increased from Jun. 2020 ($101.26 Mil) to Sep. 2020 ($106.65 Mil).

BioSpecifics Technologies's annual retained earnings increased from Dec. 2017 ($41.94 Mil) to Dec. 2018 ($72.18 Mil) and increased from Dec. 2018 ($72.18 Mil) to Dec. 2019 ($96.65 Mil).

BioSpecifics Technologies Retained Earnings Historical Data

The historical data trend for BioSpecifics Technologies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Retained Earnings Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Retained Earnings

Get a 7-Day Free Trial

19.24

30.61

41.94

72.18

96.65

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Retained Earnings	Get a 7-Day Free Trial															89.29	96.65	101.15	101.26	106.65

BioSpecifics Technologies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BioSpecifics Technologies (NAS:BSTC) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487